Bioactivx (BAX), a Singapore-based biomaterials startup, has closed its $1.43 million seed funding round led by Cocoon Capital, with participation from global strategic investors.
The firm said in a statement on Tuesday that the funding will fast-track the company’s clinical and regulatory pathway for its flagship innovation, Bioactiv® Matrix – a fully synthetic, bio-inspired skin substitute that promotes faster healing, minimal scarring, and zero risk of infection.
With the new funding, the firm will advance Bioactiv® Matrix toward global regulatory approval and commercialization.
It will also develop new products such as Bioactiv® Foam (for acute and chronic wounds) and Bioactiv® Cellulose (for ulcers and long-term care), and scale up its Singapore production facility built to ISO 13485 standards.
It is noted that each year, more than 11 million people suffer burn injuries worldwide, resulting in over 180,000 deaths according to the World Health Organization.
However, current treatments often rely on animal-derived collagen or skin grafts, which come with high infection risks, inconsistent results, and ethical or cultural barriers.
Bioactivx takes a completely new approach using a synthetic regenerative platform that mimics the body’s natural healing process without relying on animal materials.
This means no infection risk, no cold-chain storage, and no cultural restrictions, including regions where porcine- or bovine-derived products are restricted for cultural or religious reasons, making it suitable for hospitals, military, and remote environments globally.
In pre-clinical studies, Bioactiv® Matrix achieved full wound closure in just seven days and showed no inflammation by day 15, outperforming leading collagen-based products.
Early human trials also demonstrated faster recovery and cleaner healing than the current standard of care.
“Our mission is to move beyond animal-based materials and create a new class of regenerative implants that are safe, synthetic, and scalable,
“This investment will accelerate regulatory approval for Bioactiv® Matrix and expand our pipeline to treat more types of wounds and tissue injuries,” said Dr. Peili Teo, Co-founder and Director for Technology of Bioactivx®.
Meanwhile, Zongxi Sia, Investment Director at Cocoon Capital, said Bioactivx is solving a massive unmet need in wound care, and their synthetic biomaterial platform could transform regenerative medicine – offering safer, more effective, and culturally inclusive solutions.
Singapore’s Anomaly Bio raises $2.6M in pre-seed funding led by Pebblebed Ventures